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Summary Attempts to improve the selectivity of anti-cancer agents by conjugating them to antibodies
directed at tumour associated antigens have demonstrated tumour localisation but only limited therapeutic
success. We report here the advantage of a 2-stage approach in which the first component combines the
selective delivery of antibody with a capability to generate a cytotoxic agent from a second subsequently
administered component. A bacterial enzyme, carboxypeptidase G2 (CPG2) was conjugated with F(ab')2
fragment of a monoclonal antibody directed at beta subunit of human chorionic gonadotrophin (,B-hCG) and
injected into nude mice bearing hCG producing CC3 xenografts of human choriocarcinoma. Time was
allowed for the conjugate to localise at tumour sites and clear from blood before injecting para-N-bis (2-
chloroethyl) aminobenzoylglutamic acid. Cleavage of the glutamic acid moiety from this molecule by CPG2
released a benzoic acid mustard. Growth of the tumour which is resistant to conventional chemotherapy was
markedly depressed by a single course of treatment. This demonstrates for the first time the potential of an
antibody directed enzyme to activate an alkylating agent and to eradicate an established human cancer
xenograft.
The inadequate selectivity of most anticancer drugs is well
known and their toxicity to normal cell renewal tissues is
dose limiting. There have been many attempts to achieve
greater selectivity by conjugating cytotoxic substances to
antibodies which are directed at tumour associated antigens
and which have been shown to localise selectively, though
not exclusively, at cancer sites in vivo (Van Nagell et al.,
1980; Begent, 1986, Chapman et al., 1986). Limited thera-
peutic success has been achieved with antibodies alone (Shin
et al., 1976) or when conjugated to radioisotopes (Kemshead
et al., 1986), drugs (Kanellos et al., 1985), and biotoxins
(Frankel, 1985).
Eradication of cancers with cytotoxic agents requires the
agent to reach all potentially clonogenic tumour cells in
lethal concentration. There are several obstacles to achieving
this by attaching cytotoxic substances to antibodies. One is
heterogeneity in expression of suitable antigenic targets by
human cancers (Charpin et al., 1982; Primus et al., 1983)
although this may be partly overcome by multiple targeting
(Ohuchi et al., 1987). Another is that antibody penetration
of poorly vascularised tumour by antibodies is deficient so
that cytotoxic agents conjugated to antibody or antibody
fragments, fail to reach all cells with clonogenic potential
(Lewis et al., 1982). Also, the slow clearance of antibodies
from blood which may take several days (Rogers et al.,
1986) contributes to cytotoxic effects in normal tissues.
Moreover, it is evident that direct conjugation of toxin to
antibody limits the number of toxic molecules delivered to
that of antibodies reaching the tumour. Thus, when cyto-
toxic substances are coupled to antibodies, time x concen-
tration ratios for tumour and normal tissues tend to be less
favourable than is necessary for major therapeutic effect. Yet
a further problem has been that of host antibody response to
foreign protein which can prevent treatments being repeated,
but some progress in control of this response has recently
been reported (Ledermann et al., 1988a,b).
The general approach to antibody directed therapy has so
far employed conjugation of the toxic component to the
selective delivery component in a single bifunctional
molecule. Analysis of the approach suggested that it would
be advantageous to separate these functions (Bagshawe,
1987). In such a two-phase approach the selective component
would be delivered first and time allowed to optimise
localisation in the tumour and clearance from the blood
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before injecting the toxic component. It is implicit in such a
system that the toxic component must be either captured or
activated by the first. The studies described here employ
activation with an enzyme conjugated to the selective
delivery component. CPG2 an enzyme which has no known
equivalent activity acting on its specific substrate in a
tumour bearing host (Sherwood et al., 1985), has been
conjugated to F(ab')2 fragment of a monoclonal antibody
W14 (W14-F(ab')2), which is directed at ,B-hCG, with reten-
tion of the specific activity of both enzyme and antibody
(Searle et al., 1984). The conjugate localises in CC3, an hCG
producing human xenograft choriocarcinoma in nude mice
(Melton et al., 1986). It was therefore proposed that acti-
vation of prodrugs at CC3 tumour sites could be achieved by
prior localisation of the antibody-enzyme conjugate.
Materials and methods
The prodrug para-N-bis (2-chloroethyl) aminobenzoyl
glutamic acid and its benzoic acid mustard derivative, para-
N-bis (2-chloroethyl) aminobenzoic acid were synthesised by
a modification of the method of Fu (1962). Cleavage of the
glutamic acid moiety was performed with CPG2 conjugated
to F(ab')2 fragments of W14 anti-flhCG mouse monoclonal
antibody. Conversion of prodrug to drug was monitored by
change in absorbance and the Km determined from the
Michaelis-Menten plot. Chemical t112 of prodrug and drug
were determined by addition to sodium perchlorate solution
(0.1 M, 10ml) to give a final concentration of 5 x 10-3M. The
reaction was followed to completion by titration of the
released acid with NaOH (0.01 M) to a constant pH of 7.4 at
370C.
CPG2 from Pseudomonas sp. (Sherwood et al., 1985)
strain RS16 which was cloned and produced in Escherichia
coli (Minton et al., 1983) catalyses the hydrolytic cleavage of
reduced and non-reduced folates to peteroates and L-
glutamate. W14-F(ab')2 was conjugated to CPG2 using the
heterobifunctional N-maleimidobenzoyl succinimide ester
(Searle et al., 1986).
To demonstrate the conversion of prodrug to drug two
groups of 4 Nu/Nu mice with CC3 human choriocarcinoma
xenografts (Searle et al., 1981) were used. The test group
received 30U of conjugate intravenously followed 24h later
by 16mgkg-1 prodrug by the same route; controls received
saline and prodrug. 104l of blood were diluted 1:10 in saline
(0.9%) centrifuged and the supernatant applied to a pre-
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Figure 1 The prodrug para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid and its benzoic acid mustard derivative, para-N-bis
(2-chloroethyl) aminobenzoic acid formed with cleavage of glutamic acid moiety by carboxypeptidase G2.
treated C18 sample preparation cartridge. The compounds
eluted with methanol were dried in vacuo and the residue
resuspended in 35% acetonitrile:1% acetic acid. 60-90 ul was
injected into a C18 micro Bondapak (5tim) column run in
the same solvent at 1 mlmin- and the compounds detected
at 305nm. Retention times were 5min for the prodrug and
15min for the drug.
Mean prodrug and drug concentrations were measured in
normal tissues and CC3 xenografts. Prodrug was adminis-
tered intraperitoneally 48 h after intravenous injection of
W14-F(ab')2:CPG2 (3 units enzyme activity). The tissues were
excised 0.5h later and frozen at -70° till analysed.
Cytotoxicity of prodrug and drug were tested against JAR
human choriocarcinoma cells (5 x 104ml-1 grown in DMEM
(16) and treated with prodrug or drug in the concentration
5-800gM three times at 24-h intervals. CPG2 (6Uml-1 final
concentration) was added to equivalent cultures with each
dose of prodrug to achieve active drug in situ. Cell viability
was determined by haemocytometry 24h after the last
treatment.
The effect of antibody enzyme conjugate and prodrug on
the growth of CC3 xenografts was compared with saline
controls and other controls receiving standard chemo-
therapeutic agents. The tumours were just palpable on day 1
and all mice had serum HCG >40IUI1. Tumours were
measured twice weekly in 3 diameters and recorded as
volume (Ildl.d2.d3/6) relative to that on day 1. One group of
4 mice received W14 F(ab')2 intravenously (50U enzyme/
mouse) and 56, 72 and 80h later were given 5mg prodrug in
DMSO/PBS (1:5) intravenously. A second group received
10mg of prodrug 72, 88 and 96h later. These treatments
were not repeated.
Further groups of 4 mice received intravenously, metho-
trexate 5mgkg-1, or hydroxyurea 50mgkg-1, or cytosine
arabinoside 20mgkg-1, at 0, 16 and 24h. The 3-dose
treatment was repeated weekly until tumour growth required
sacrifice. (The mice receiving cytosine arabinoside received 3
doses only).
Other groups of 4 mice in similar condition, received
saline in lieu of conjugate and prodrug; or conjugate alone
(50 units enzyme); or drug (2.5mg/mouse x 3 which was
maximum tolerated dose); or prodrug alone (10mg/
mouse x 3, maximum tolerated dose 22.5mg x 3).
Results
The prodrug para-N-bis (2-chloroethyl) aminobenzoyl
glutamic acid and its derivative para-N-bis (2-chloroethyl)
aminobenzoic acid are shown in Figure 1. The extinction
coefficient at pH 7.3 and 320nm was found to be
9,208 Lmol- 1cm-1 for prodrug and 2,062 Lmol-1 cm-1 for
drug. CPG2 whether free or conjugated to an antibody
cleaves the glutamic acid moiety of the prodrug with high
affinity (Km=4.9pM) leaving an active benzoic acid mustard.
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Figure 2 Conversion of prodrug to drug in serum of two groups
of 4 Nu/Nu mice with CC3 human choriocarcinoma xenografts
receiving antibody enzyme conjugate or saline controls. The test
group received 30 units of conjugate intravenously followed 24h
later by 16mgkg - prodrug by the same route (0 prodrug, U
drug); controls received saline and prodrug (O prodrug, A drug).
The chemical half lives of the prodrug and drug are 16.5h
and 5.3h respectively.
Evidence of conversion of prodrug to drug in vivo was
obtained from blood samples taken from xenografted nude
mice and the ratio of prodrug to drug when prodrug was
given 24h after administration of W14-F(ab')2:CPG2 conju-
gate is shown in Figure 2. It is evident that in the presence
of conjugate, conversion of prodrug to drug readily occurred
with little residual prodrug detectable in plasma. In the
absence of conjugate, low levels of drug were detected but
only 3h after injection of the prodrug. The distribution of
prodrug and drug in tissues in a similar experiment is shown
in Table I. At 0.5h after prodrug administration prodrug
was detectable at all sites except in tumour, a finding
consistent with more complete conversion of prodrug to
drug at that site than in other tissues.
In vitro evidence of cytotoxicity of prodrug and drug on
JAR cells is shown in Figure 3. ID50 for drug was 20pM,
whereas prodrug alone at 800gM concentration gave only
17% inhibition of control. In the presence of CPG2, prodrug
gave an ID50 of 8pM. No loss of viability was detected in
the presence of enzyme alone.
In vivo evidence of antitumour activity is shown in Figure
4. Groups receiving conjugate and prodrug showed marked
suppression of tumour growth (Figure 4a). Prodrug alone
produced slight growth delay. Tumours in mice receiving702 K.D. BAGSHAWE et al.
Table I Mean prodrug and drug concentrations
(ugg-1) in normal tissues and CC3 xenografts in
Nu/Nu mice. Prodrug was administered intra-
peritoneally 48h after intravenous injection of
W14-F(ab')2:CPG2 (30U enzyme activity). The
tissues were excised 0.5h later
Tissue Prodrug Drug
Tumour <0.05 0.86
Liver 22.0 7.5
Kidney 2.9 2.8
Lung 0.20 2.5
Gut 12.3 1.3
Spleen 0.51 1.5
Brain 0.16 0.65
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Figure 3 Cytotoxicity of prodrug and drug against JAR human
choriocarcinoma cell line. JAR cells (5 x 104/ml) were grown in
DMEM and treated with prodrug ( 0) or drug (0) in the
concentration range 5-800yM three times at 24h intervals. CPG2
(6Uml1 final concentration) was added to equivalent cultures
with each dose of prodrug (A) to achieve active drug in situ.
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conventional cytotoxic agents, given in full dosage three
times in a 24-h period, at weekly intervals, showed either
growth at a similar rate to saline controls or accelerated
growth. Drug alone given at maximum tolerated dose
showed no inhibition of tumour growth (Figure 4b).
Discussion
The principle of converting relatively inert prodrugs into
active cytotoxic agents by enzymes is well established but
this has not been achieved specifically at cancer sites,
because human cancers have not been found to exhibit
intrinsic enzymic activity sufficiently distinctive from normal
tissues. The aij 'ity of a localised non-mammalian enzyme to
generate an effective concentration of cytotoxic molecules
from an appropriate prodrug in a tumour is indicated by the
marked inhibition of growth achieved here in contrast to the
ineffectiveness of the drug and of conventional cytotoxic
agents given intravenously.
The tumour and prodrug used here constitute a rigorous
test for this approach. The target antigen is freely secreted
by differentiated syncytiotrophoblastic cells but not by the
clonogenic cytotrophoblast cells (Midgley & Pierce, 1962)
and the antibody-enzyme conjugate encounters a high
concentration of antigen in body fluids. The CC3 tumour as
shown here is resistant to a wide range of conventional
cytotoxic agents. Although the prodrug biological t112
(biphasic =a 0.32h, #= 1.8 h) was satisfactory the active
drug has an undesirably long half-life (biphasic a=0.5h, and
,B=1.7h) allowing it time to diffuse away from activation
sites and to exert toxic effects. Despite these limitations it is
encouraging that marked inhibition of growth of this tumour
was observed with a single course of treatment.
An antibody-enzyme conjugate is unlikely to have better
penetration or more uniform distribution within a tumour
than antibody itself, but activation of a prodrug at tumour
sites by the enzyme has several potential advantages. The
prodrug can be relatively inert and have a long biological
half-life. It is desirable that the drug released from the
prodrug should be small, readily diffusible and able to enter
cells, or be toxic at membrane sites whether or not they
express target antigen. The limitations of poor penetration
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Figure 4 Growth curves for CC3 choriocarcinoma xenografts in Nu/Nu mice following injection with various agents.
(a) Two groups of 4 mice received W14 F(ab')2:CPG2 intravenously (50 units enzyme/mouse) and 56, 72 and 80h later; one
group (0) were injected intravenously with 5mg prodrug in DMSO/PBS (1:5); the other group (0) received 1Omg of prodrug 72,
88 and 96h later. These treatments were not repeated.
Further groups of 4 mice received standard chemotherapeutic iv: methotrexate 5mgkg 1 (O); hydroxyurea 50mgkg1 (A);
actinomycin D 7.5jgkg-I (X); cyclophosphamide 20mgkg- (El); cytosine arabinoside 20mgkg-1 (A) at 0, 16 and 24h. The 3-
dose treatment was repeated weekly until tumour growth required sacrifice, except for mice receiving cytosine arabinoside which
received 3 doses only.
(b) Mice in similar condition to those in 4(a) received saline in lieu of conjugate and prodrug (A); or conjugate alone (50 units
enzyme) (A); drug (2.5 mgmouse-1 x 3 which was maximum tolerated dose) (0); or prodrug alone (10 mgmouse-1 x 3, maximum
tolerated dose 22.5mg x 3) (0).
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by antibody and heterogeneity in distribution of target
antigen can therefore be overcome. Normal tissues can be
protected by the favourable distribution of the activating
enzyme and by ensuring that the released active drug has a
short half-life. In this way it should be possible to generate
prolonged high concentrations of cytotoxic drugs in antibody
binding tumours without inducing serious normal tissue
toxicity. Drug resistance is potentially avoidable by mass
drug action and if necessary, by multiple prodrugs.
The first drug we have tested in this system falls short of
the ideal mainly with respect to its prolonged half-life. It is
evident however that various classes of prodrug can be
synthesised for activation by a range of matching enzymes of
non-human origin. Translation of this approach to the clinic
is likely to encounter logistical problems in the production of
antibody-enzyme conjugate on a large enough scale whether
by chemical conjugation or genetic engineering. These
problems now need to be addressed.
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